Discovery of pyrimidine benzimidazoles as Lck inhibitors

Part I

Guobao Zhang, Pingda Ren, Nathanael S. Gray, Taebo Sim, Yi Liu, Xia Wang, Jianwei Che, Shin Shay Tian, Mark L. Sandberg, Tracy A. Spalding, Russell Romeo, Maya Iskandar, Donald Chow, H. Martin Seidel, Donald S. Karanewsky, Yun He

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

A series of 4-amino-6-benzimidazole-pyrimidines was designed to target lymphocyte-specific tyrosine kinase (Lck), a member of the Src kinase family. Highly efficient parallel syntheses were devised to prepare analogues for SAR studies. A number of these 4-amino-6-benzimidazole-pyrimidines exhibited single-digit nanomolar IC50s against Lck in biochemical and cellular assays. These 4-amino-6-benzimidazole-pyrimidines represent a new class of tyrosine kinase inhibitors.

Original languageEnglish
Pages (from-to)5618-5621
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume18
Issue number20
DOIs
Publication statusPublished - 2008 Oct 15
Externally publishedYes

Fingerprint

Benzimidazoles
Pyrimidines
Lymphocytes
Protein-Tyrosine Kinases
src-Family Kinases
Assays
pyrimidine
benzimidazole

Keywords

  • Autoimmune disease
  • Kinase inhibitor
  • Lck inhibitor
  • Pyrimidine benzimidazoles
  • Transplantation rejection

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Zhang, G., Ren, P., Gray, N. S., Sim, T., Liu, Y., Wang, X., ... He, Y. (2008). Discovery of pyrimidine benzimidazoles as Lck inhibitors: Part I. Bioorganic and Medicinal Chemistry Letters, 18(20), 5618-5621. https://doi.org/10.1016/j.bmcl.2008.08.104

Discovery of pyrimidine benzimidazoles as Lck inhibitors : Part I. / Zhang, Guobao; Ren, Pingda; Gray, Nathanael S.; Sim, Taebo; Liu, Yi; Wang, Xia; Che, Jianwei; Tian, Shin Shay; Sandberg, Mark L.; Spalding, Tracy A.; Romeo, Russell; Iskandar, Maya; Chow, Donald; Martin Seidel, H.; Karanewsky, Donald S.; He, Yun.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 18, No. 20, 15.10.2008, p. 5618-5621.

Research output: Contribution to journalArticle

Zhang, G, Ren, P, Gray, NS, Sim, T, Liu, Y, Wang, X, Che, J, Tian, SS, Sandberg, ML, Spalding, TA, Romeo, R, Iskandar, M, Chow, D, Martin Seidel, H, Karanewsky, DS & He, Y 2008, 'Discovery of pyrimidine benzimidazoles as Lck inhibitors: Part I', Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 20, pp. 5618-5621. https://doi.org/10.1016/j.bmcl.2008.08.104
Zhang, Guobao ; Ren, Pingda ; Gray, Nathanael S. ; Sim, Taebo ; Liu, Yi ; Wang, Xia ; Che, Jianwei ; Tian, Shin Shay ; Sandberg, Mark L. ; Spalding, Tracy A. ; Romeo, Russell ; Iskandar, Maya ; Chow, Donald ; Martin Seidel, H. ; Karanewsky, Donald S. ; He, Yun. / Discovery of pyrimidine benzimidazoles as Lck inhibitors : Part I. In: Bioorganic and Medicinal Chemistry Letters. 2008 ; Vol. 18, No. 20. pp. 5618-5621.
@article{1c10d6de235e4450a5d85e11d48b9c63,
title = "Discovery of pyrimidine benzimidazoles as Lck inhibitors: Part I",
abstract = "A series of 4-amino-6-benzimidazole-pyrimidines was designed to target lymphocyte-specific tyrosine kinase (Lck), a member of the Src kinase family. Highly efficient parallel syntheses were devised to prepare analogues for SAR studies. A number of these 4-amino-6-benzimidazole-pyrimidines exhibited single-digit nanomolar IC50s against Lck in biochemical and cellular assays. These 4-amino-6-benzimidazole-pyrimidines represent a new class of tyrosine kinase inhibitors.",
keywords = "Autoimmune disease, Kinase inhibitor, Lck inhibitor, Pyrimidine benzimidazoles, Transplantation rejection",
author = "Guobao Zhang and Pingda Ren and Gray, {Nathanael S.} and Taebo Sim and Yi Liu and Xia Wang and Jianwei Che and Tian, {Shin Shay} and Sandberg, {Mark L.} and Spalding, {Tracy A.} and Russell Romeo and Maya Iskandar and Donald Chow and {Martin Seidel}, H. and Karanewsky, {Donald S.} and Yun He",
year = "2008",
month = "10",
day = "15",
doi = "10.1016/j.bmcl.2008.08.104",
language = "English",
volume = "18",
pages = "5618--5621",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "20",

}

TY - JOUR

T1 - Discovery of pyrimidine benzimidazoles as Lck inhibitors

T2 - Part I

AU - Zhang, Guobao

AU - Ren, Pingda

AU - Gray, Nathanael S.

AU - Sim, Taebo

AU - Liu, Yi

AU - Wang, Xia

AU - Che, Jianwei

AU - Tian, Shin Shay

AU - Sandberg, Mark L.

AU - Spalding, Tracy A.

AU - Romeo, Russell

AU - Iskandar, Maya

AU - Chow, Donald

AU - Martin Seidel, H.

AU - Karanewsky, Donald S.

AU - He, Yun

PY - 2008/10/15

Y1 - 2008/10/15

N2 - A series of 4-amino-6-benzimidazole-pyrimidines was designed to target lymphocyte-specific tyrosine kinase (Lck), a member of the Src kinase family. Highly efficient parallel syntheses were devised to prepare analogues for SAR studies. A number of these 4-amino-6-benzimidazole-pyrimidines exhibited single-digit nanomolar IC50s against Lck in biochemical and cellular assays. These 4-amino-6-benzimidazole-pyrimidines represent a new class of tyrosine kinase inhibitors.

AB - A series of 4-amino-6-benzimidazole-pyrimidines was designed to target lymphocyte-specific tyrosine kinase (Lck), a member of the Src kinase family. Highly efficient parallel syntheses were devised to prepare analogues for SAR studies. A number of these 4-amino-6-benzimidazole-pyrimidines exhibited single-digit nanomolar IC50s against Lck in biochemical and cellular assays. These 4-amino-6-benzimidazole-pyrimidines represent a new class of tyrosine kinase inhibitors.

KW - Autoimmune disease

KW - Kinase inhibitor

KW - Lck inhibitor

KW - Pyrimidine benzimidazoles

KW - Transplantation rejection

UR - http://www.scopus.com/inward/record.url?scp=53449083913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53449083913&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2008.08.104

DO - 10.1016/j.bmcl.2008.08.104

M3 - Article

VL - 18

SP - 5618

EP - 5621

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 20

ER -